summari report result forecast
ep estim slightli consensu
sale estim organ in-lin
consensu estim analysi im data suggest strength
sever us drug see pharma tracker start page
thu increas us pharma forecast
net howev increment wors fx headwind nearli
off-set us pharma forecast rais
analysi nielsen data suggest deceler us consum
growth direct consist model
two consecut quarter sale growth guidanc increas see
lower likelihood anoth rais current
addit increment fx headwind see low probabl
report ep guidanc rais current forecast organ
sale growth guidanc report ep
guidanc expect jnj sale growth
acceler start continu continu
improv three key busi unit includ rebound
pharma growth exceed market howev due
increas fx headwind next year lower ep
estim assum abl off-set
increment currenc drag
pharma consum growth deceler forecast
total sale organ sale growth
repres deceler due
tougher comp consum increas generic/biosimilar
headwind pharma analysi im data indic stronger-
than-expect perform number key us drug thu
increas us pharma sale forecast net
consum nielsen data show deceler us consum
growth direct consist
forecast us consum sale growth vs
due tougher comp
see lower likelihood guidanc rais guid
organ sale growth report ep
rais full year sale growth guidanc
believ smaller chanc anoth guidanc
rais addit math suggest fx headwind
may wors guidanc year
translat cent increment ep impact
see low probabl ep guidanc rais expect jnj
pharma busi grow in-lin market medic
devic consum segment grow market
forecast sale organ ep
vs consensu respect
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
ep estim slightli consensu forecast ep
consensu estim lower total revenu forecast
adjust organ growth in-lin consensu expect model forecast net non-
oper incom includ gain asp divestitur
line often difficult forecast may account least differ
consensu ep forecast
growth expect deceler pharma consum report result
estim total sale organ ep vs consensu
respect rais forecast sever jnj key drug us reflect
stronger-than-expect im trend howev offset rais estim increas fx
headwind quarter estim organ pharma sale growth compar
growth deceler reflect increas impact us biosimilar gener
competit consum estim organ growth vs reflect tough yr/yr
comp reflect babi care brand relaunch prior year period analysi nielsen data
point deceler us consum growth direct consist forecast
medic devic model organ sale growth forecast assum close
fx headwind nearli doubl month ago
im data point stronger expect perform sever key us drug base
im analysi rais us sale forecast zytiga tremfya simponi/aria
aggreg partli off-set lower imbruvica sale estim chang sale
forecast us remicad darzalex im analysi suggest forecast may prove somewhat
conserv although magnitud potenti upsid probabl modest also note
forecast us xarelto tracleer sale appear reason rel extrapol im sale rang
declin price due gener competit tracleer creat uncertainti reliabl
im extrapol forecast us pharmaceut sale yr/yr declin compar
organ growth flattish adjust prior period price adjust detail
product tracker analysi start page
expect consum growth deceler due tougher comp jnj ww consum sale
grew acceler larg reflect easier comp expect ww
consum organ sale growth slow due much tougher comp recal ww consum
sale grew organ began relaunch babi brand led
stock benefit quarter analysi aggreg nielsen data
suggest growth deceler us consum would
direct consist outlook us consum growth estim
figur nielsen data appear trend direct in-lin report us consum sale growth
time notabl quarterli variat figur ww basi forecast
consum sale organ growth includ us sale
ex-fx compani report secur llc estim organ growth adjust fx acquisitions/divestitur sell day prior price adjust pharma venezuela anima exit pharma overal growth adjust remicad rebat ex-adjust organ growth pharma overal cardiovascular cerenovu neurovascular intervent solut start diabet adjust anima exit impact amo acqusit includ ex-fx growth rate atln acquisit includ ex-fx growth rate key busi segment johnson johnson
nielsen sale base aggreg data
nielsen sale base aggreg data
lower likelihood anoth sale growth guidanc rais rais adjust organ
sale growth ex-fx acquisit divestitur put current rang
growth rais part due gener biosimilar headwind estim
call benign expect analysi im suggest gener biosimilar
headwind continu acceler gener zytiga eros still appear benign
expect would also note rais underli sale growth guidanc
suggest posit growth momentum busi net-net see
reduc probabl anoth sale growth guidanc rais two consecut quarter guidanc
rais although would rule caveat limit visibl
busi outsid us pharma/consum model assum jnj pharma busi
essenti grow in-lin market medic devic consum segment trail market
growth net organ sale growth report sale figur
headwind thu year estim fx impact nearli vs prior
estim repres nearli increment drag sale slight worsen
currenc impact also extend result increment fx headwind vs jnj
guidanc assum similar drop-through bottom-lin translat
addit ep vs current guidanc fx drag believ
absorb increment fx headwind ep year lower
report sale forecast due fx chang ep forecast year
ep guidanc rais less like due increment fx headwind call reiter
report ep guidanc growth midpoint rang guidanc includ
fx headwind oper ep guidanc growth believ
absorb addit fx headwind seem less like increas full year ep
guidanc model assum complet share buy-back program year
complet report could contribut annual earn accret chang
report ep estim yr/yr growth in-lin consensu forecast
expect underli top-lin growth reacceler start continu
fx becom bigger headwind next year forecast jnj organ sale grow
slight improv estim driven acceler growth medic devic
pharma forecast organ sale growth vs estim
acceler growth outlook larg reflect improv sale growth
estim year next year reflect tough comp primarili due gener
zytiga headwind lesser extent gener tracleer biosimilar procrit impact addit
divestitur slower growth busi like asp steadi cadenc new product launch
expect growth medic devic busi continu improv consum look
steadi growth trend seek stabil key segment like beauti babi over-the-counter
said fx repres estim growth headwind vs previou modest
drag assum similar drop-through ep impact fx approxim math
recent updat opioid litig encourag uncertainti opioid litig
jnj potenti liabil overhang stock sever recent updat
howev encourag reinforc view damages/settl like
manag especi given strong balanc sheet specif ok case
order pay significantli less request plaintiff plan appeal
decis could lead reduct payment repres
estim cost entir abat program jnj portion addit recent oh
opioid case settl without admiss liabil remov feder trial
due start oct case repres two datapoint believ help
estim ultim liabil continu see refer
cash end
estmkt compani report secur llc estim organ growth report ex-fx adjust sell day differ venezuela impact prior period price johnson johnson
us remicad sale forecast seem appropri slightli conserv estim
us remicad ex-export sale yr/yr declin compar qtd jul-aug im
sale declin yr/yr direct report us remicad sale declin somewhat
sever im sale declin past sever quarter exampl adjust
report sale exclud rebat adjust prior year vs im sale report
sale vs im sale assum us remicad sale declin acceler sep
im sale declin would reach mid- high-teen current forecast declin seem
reason slightli conserv
biosimilar remicad penetr continu inch im sale show biosimilar remicad
sale continu inch ytd im sale total oct compar jan
nearli aug figur growth biosimilar remicad sale driven
pfe/celltrion inflectra mrk renflexi meanwhil trail averag remicad im sale
slightli compar sale rang earlier year appear
direct consist eros report sale due increas rebat discount im
sale show inflectra account biosimilar remicad im sale share
start year
biosimilar procrit uptak remain ahead biosimilar remicad year pfe biosimilar procrit
retacrit launch sale ramp to-dat appear move faster initi
biosimilar remicad launch specif im sale show retacrit sale aug
decemb time jnj procrit im sale fallen
respect month retacrit market uptak
ahead inflectra uptak first year forecast us procrit sale
yr/yr compar forecast seem reason base
spravato balversa us sale larg track new spravato indic expect
receiv fda approv spravato treatment resist depress balversa bladder
cancer earlier year spravato distribut limit physician must certifi prescrib
product data limit given earli natur launch extrapol im sale spravato total
nearli compar estim spravato trx averag per week
past month averag per week june earli oct file label
expans spravato includ rapid reduct depress symptom patient suicid ideat
believ clinic data warrant fda approv especi given lack treatment option
patient group would view new indic increment growth driver spravato start
balversa extrapol im sale total bit shi estim
howev given balversa limit distribut remain seen well im data captur
growth model us darzalex sale yr/yr growth ww sale
increas yr/yr although us forecast slighlti extrapol im sale
chang estim given modest magnitud potenti upsid forecast
ww darzalex sale in-lin genmab estim darzalex approv front-lin
use us transplant elig inelig patient could help acceler sale
growth come quarter call genmab state expect darzalex sale grow
rapidli us market share increas front line second line set
also lead longer durat treatment accord brandimpact darzalex share front-lin
mm multipl myeloma rose aug follow front-lin maia approv late
june expect darzalex line share continu climb late especi
approv cassiopeia approv transplant elig patient late sep darzalex held share
line share line mm market aug repres product respect
segment figur darzalex held overal market share brandimpact survey
lower us imbruvica sale forecast us imbruvica revenu impli
end-us sale seem bit high compar extrapol im sale closer
impli revenu lower us imbruvica
revenu yr/yr coupl increment fx headwind
forecast ww imbruvica revenu translat revenu
would slightli abbv guidanc rx perspect roll
imbruvica volum grew weekli exce figur
call note imbruvica remain market leader cll across line therapi new
patient share front-lin set share
chang us invokana sale forecast estim us invokana sale estim
yr/yr seem in-lin extrapol im sale invokana
franchis volum fell jul/aug consist ytd perform suggest potenti
stabil franchis figur im data first three week sep show similar yr/yr rx
volum declin figur invokana franchis nrx share class
rel stabl past month competitor boehring ingelheim lli jardian
franchis remain leader categori nrx share nrx volum
growth aug figur recal jardianc empa-reg outcom trial show drug lower
cardiovascular risk without increas amputation/fractur risk categori nrx growth averag
ytd vs growth
increas us zytiga sale estim us gener zytiga competit began decemb
impact benign anticip to-dat gener eros
acceler still remain somewhat expect extrapol im sale
suggest us zytiga sale could exceed compar previou estim
yr/yr declin comparison zytiga trx nrx volum yr/yr to-dat
addit jnj gener zytiga continu perform well share similar level
ahead apotex myl share rais us zytiga sale estim
assum could discounts/reb accrual fulli
reflect im sale zytiga held abirateron share aug may
februari
erleada uptak continu measur pace new indic support continu
posit momentum nearli month sinc launch erleada us sale annual nearli
base aug im sale annual im sale start year monthli
erleada trx nrx volum increas slowli ytd estim us erleada sale
slightli extrapol im sale quarter chang
forecast given small magnitud differ erleada label expand mid-sep includ
metastat castration-sensit prostat cancer mcspc new indic late quarter like
limit impact help drive stronger erleada uptak
discounting/reb xarelto appear continu increas forecast us xarelto sale
q/q yr/yr forecast appear reason rel
extrapol im sale rang differ report im sale
continu widen past quarter render histor ims/report sale ratio less
meaningful/reliab forecast addit report four consecut quarter sequenti
declin flattish xarelto sinc suggest continu pressur product despit
expand label cad/pad coronari arteri disease/peripher arteri diseas xarelto rx volum
continu grow mid- high-singl digit growht yr/yr figur declin sale suggest
decreas net price aug eliqui maintain lead among noac share
m/m follow xarelto share m/m past year xarelto lost share
eliqui gain share figur noac account oral anticoagul
nrx end figur oct fda approv xarelto use
cad/pad coronari arteri disease/peripher arteri diseas im sale trend suggest xarelto
cad/pad ad franchis growth
us invega sustenna/trinza im sale well trend forecast us sale
growth yr/yr within extrapol im sale rang howev note jul/aug
im sale jnj long-act inject atyp laia franchis sustenna trinza risperd consta
yr/yr consist trend inconsist previou histor trend
larg double-digit growth franchis figur note report us invega
sustenna/trinza sale growth yr/yr despit im sale prior year
still unclear us chang im calcul data sourc could affect
apr-aug data maintain forecast note uncertainti im
data us laia market maintain lead franchis nrx market share
past month ostuka abilifi maintena hold share yr/yr
aristada share yr/yr figur
chang us stelara sale forecast uc indic help maintain strong
growth momentum forecast us stelara sale yr/yr growth within
extrapol im sale rang stelara im sale grew jul/aug
suggest possibl acceler despit continu strong uptak tremfya
figur stelara trx volum specialti continu show crohn key growth driver
growth volum written gastroenterolog specialist past year partli
off-set declin volum written dermatologist stelara stelara
recent approv eu ulcer coliti uc would expect us approv near-term
file dec help maintain sale growth momentum
increas us tremfya sale forecast rais us tremfya sale
base extrapol im sale rang report sale track
rel consist im sale sinc launch year market tremfya im sale
annual base jul/aug data comparison nv cosentyx lli taltz sale
annual close respect time post-launch current cosentyx im
sale annual taltz im sale annual weekli tremfya volum
continu track well ahead stelara remain behind cosentyx taltz time post-
launch figur believ tremfya remain key growth driver head sun
pharma ilumya continu see littl traction market one year post launch
rais us simponi/aria sale estim increas us simponi/aria sale
forecast base extrapol im sale rang forecast
impli growth yr/yr compar growth easi comp jul/aug simponi im
sale grew aria im sale nearli togeth drive franchis growth
repres acceler franchis growth reflect easier comp figur
repres first full quarter gener tracleer complet forecast us tracleer sale
yr/yr declin due start gener competit mid-jun extrapol im sale
total quarter chang forecast howev due earli natur gener
eros uncertainti around magnitud discount rebat accrual rest us
pah peripher arteri hypertens franchis forecast us opsumit sale uptravi
sale rel consist extrapol im sale rang
respect figur note greater variabl
report sale im sale vari quarter quarter product pah franchis
compar product track via im
analysi independ arriv secur llc basi data
inform im respons relianc recipi either data analys
 us split im health incorpor nation sale perspect compani report secur llc estim sale estim base commentari im data us nucynta nucynta er sold forecast us imbruvica sale assum record end-us sale report consist third month perform prior quarter assum septemb im sale repres medic technolog
compris mostli pfe/celltrion inflectra
figur darzalex hold posit line multipl myeloma market
figur darzalex maintain lead line multipl myeloma market
follow chang imbruvica ndc nation drug code im report doubl count rx
one distributor late march continu part year
rxtrxnrxfeb cll approvedmar front-lin cll approvedjul r/r cll label expans includ mutat jan waldenstrm macroglobulinemia approvedaug graft-vs-host-diseas cgvhd growthmonthli trxtrx volumetrx rx y/i present canva data ada meet -posit efficaci safeti trade-off strengthen warn risk acut kidney add black box warn leg foot amput risk medic technolog
figur invokana franchis continu lose share
figur zytiga erleada monthli volum growth trend
new oral anticoagul includ pradaxa xarelto eliqui savaysa
growth trxtrx growthtrx nrxnrxoral anticoagulantsnew oral anticoagul new oral anticoagul xarelto spaf approvedeliqui spaf approvedsavaysa spaf approvedeliqui dvt treatment approvedxarelto dvt treatment approvedeliqui dvt prevent approv medic technolog
growthim sale sustenna trinza consta sale yoy im sale growthsustenna launch aug launch jun market sharealk aristadaotsuka abilifi maintenajnj sinvega sustenna trinza risperd growthsal stelara tremfya salesstelara tremfya yoy growthtremfya launch jul launch may crohn launch sep launch jan johnson johnson
figur atln opsumit im sale maintain growth momentum
figur atln tracleer im sale declin
figur atln uptravi im sale remain solid launch trajectori
price target nc
price target impli cash ep base sum-of-the-part
analysi risk includ delay pipelin product unexpect delay deal integr unexpect
deterior industri
expect growth slow due multipl headwind see growth re-acceler
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product cardiovascular orthoped surgic vision compani report sale
year-over-year organ basi
sale trxtrxim salesstart gener sale trxtrxim sale johnson johnson
